Immunocompromised Host Infections

Immunocompromised host infections are the infections that arise when the immune system is weakened by disease or therapy. Rather than a single illness, this is a framework for predicting and interpreting infection according to the nature, depth, and duration of the host's immune defect and the epidemiologic exposures the host has encountered.

Definition

Immunocompromised host infections are infections occurring in patients whose immune defenses are impaired by congenital deficiency, disease, or immunosuppressive therapy, in whom the spectrum and severity of infection are shaped by the specific defect and the timing of exposures.

Scope

This topic covers how different categories of immune compromise, neutropenia, impaired cell-mediated immunity, humoral and complement deficiency, splenic dysfunction, and barrier disruption, change susceptibility to infection, with transplantation and cancer therapy as central clinical settings. It is a conceptual reference, not a prescriptive prophylaxis or treatment protocol.

Core questions

• How does the type of immune defect determine which infections occur?
• How do the net state of immunosuppression and epidemiologic exposures combine to define risk?
• Why does the timeline after transplantation predict particular infections?

Key concepts

• Net state of immunosuppression
• Neutropenia and bacterial/fungal risk
• Cell-mediated immune defects and intracellular pathogens
• Humoral and splenic defects and encapsulated bacteria
• Timeline of infection after transplantation
• Barrier disruption and device-associated infection

Mechanisms

Susceptibility in the immunocompromised host is governed by which defense is impaired and how severely. Defects in innate sensing and inflammation blunt early containment of microbes (Takeuchi & Akira, 2010); neutropenia opens the door to bacterial and mould infections; deficient cell-mediated immunity favours intracellular pathogens, fungi, and viral reactivation; and humoral or splenic defects raise the risk from encapsulated organisms. Fishman's framework for the transplant recipient combines the net state of immunosuppression with epidemiologic exposures and a characteristic time-course to predict the responsible pathogens at each phase after transplantation (Fishman, 2007).

Clinical relevance

Characterising the immune defect helps clinicians anticipate the plausible pathogens and provides the conceptual basis for prophylaxis in defined high-risk groups. This entry is educational and explains the reasoning framework; it does not provide individualised diagnostic criteria, drug regimens, or management decisions.

Epidemiology

The population at risk has expanded markedly with the growth of solid-organ and haematopoietic stem-cell transplantation, intensive chemotherapy, and the increasing use of biologic and other immunosuppressive agents. In each of these settings the burden and pattern of infection follow the depth and type of immune suppression, and structured prophylaxis has reshaped which infections are seen (Fishman, 2007; Aberg et al., 2013).

History

A systematic approach to infection in the immunocompromised host developed alongside transplantation medicine in the late twentieth century, when clinicians recognised that the risk of infection could be understood as the interaction of the net state of immunosuppression with environmental exposures, unfolding along a predictable timeline after transplantation (Fishman, 2007).

Key figures

• Jay Fishman
• Robert Rubin

Seminal works

• fishman-2007

Frequently asked questions

Does being immunocompromised always mean the same infection risk?

No. The risk depends on which part of the immune system is impaired and how severely. Loss of neutrophils, defective cell-mediated immunity, and loss of antibody or spleen function each predispose to different groups of organisms.

Why does infection risk after a transplant follow a timeline?

The intensity of immunosuppression and the relevant exposures change over the weeks and months after transplantation, so different infections tend to occur at different phases. This time-course helps clinicians anticipate the most likely pathogens at each stage.